Charles River Labs Posts Major 2025 Loss on Write-Downs, Eyes 2026 Rebound

WILMINGTON, Mass. – February 18, 2026 – Charles River Laboratories International, Inc. (NYSE: CRL) capped a challenging 2025 with a significant net loss, driven by hundreds of millions of dollars in asset write-downs, yet company leadership is signaling a turnaround, citing stabilizing client demand and a cautiously optimistic outlook for 2026. The contract research giant reported a GAAP net loss of $144.3 million for the full year, a stark reversal from the prior year's income, highlighting persistent headwinds in specific business units.

Navigating a Year of Write-Downs

The story of Charles River's 2025 financial performance is dominated by substantial non-cash charges that pushed its bottom line deep into the red. The fourth quarter alone saw a GAAP net loss of $276.6 million, largely stemming from a $211.0 million intangible asset impairment and a $165.0 million goodwill impairment.

These write-downs were concentrated in two key areas: the Biologics Solutions reporting unit within the Manufacturing segment, and the Cell Solutions business within the Research Models and Services (RMS) segment. The Manufacturing segment, which includes contract development and manufacturing (CDMO) services, was particularly hard-hit. The company recorded a $108.9 million impairment for its CDMO Gene Therapy assets and a $102.0 million impairment for its Cell Solutions assets.

Analysis of the company's performance reveals these impairments follow a period of underperformance, particularly in the cell and gene therapy space, which has not grown as robustly as anticipated following key acquisitions. The loss of a major commercial cell therapy client during the year, which trimmed nearly $25 million from revenue, underscored the competitive pressures and volatility in this advanced manufacturing sector. These factors triggered the revaluation of the assets' carrying value, leading to the massive write-downs.

While the GAAP figures paint a grim picture, the company's non-GAAP results, which exclude these impairments and other one-time items, offer a different perspective. For the full year, non-GAAP diluted earnings per share came in at $10.28, a marginal decrease of just 0.4% from $10.32 in 2024. This suggests that the core operational profitability of the business remained relatively stable, insulating it from the full impact of the accounting charges.

A Bellwether for Biopharma?

Despite the financial setbacks, the most crucial indicator for the company's future may lie in its order book. Management highlighted a "substantial improvement in DSA net bookings" during the fourth quarter. The Discovery and Safety Assessment (DSA) segment, the company's largest, achieved a net book-to-bill ratio of 1.12x, meaning it booked 12% more new business than it recognized in revenue during the quarter.

This metric is a critical forward-looking indicator for the contract research industry and is being interpreted as a sign of a potential rebound. After a period of budgetary caution and funding challenges, particularly among small and mid-sized biotech clients, this uptick in bookings suggests that biopharmaceutical R&D pipelines are beginning to flow more freely.

In the company's earnings announcement, Chair, President and CEO James C. Foster pointed to these trends as evidence of "the stabilization of the biopharmaceutical demand environment." This cautious optimism is central to the company's 2026 forecast, as the strong bookings from late 2025 are expected to convert into revenue as the new year progresses. The performance of Charles River's DSA segment is often viewed as a barometer for the health of the broader preclinical drug development market, and this positive signal will be watched closely by industry analysts.

A Strategic Reshaping

Charles River is not passively waiting for the market to recover. The company is actively reshaping its portfolio and operations to improve profitability and focus on its core strengths. A key part of this strategy involves planned divestitures of businesses that currently account for approximately 7% of annual revenue. While the specific units have not been publicly named, the company expects these sales to be completed by mid-2026 and to be accretive to non-GAAP earnings.

Simultaneously, the company is making targeted investments to address operational challenges. The recent acquisition of the assets of K.F. (Cambodia) Ltd. is a direct response to persistent supply chain issues and high costs associated with non-human primates (NHPs), which are critical for safety and efficacy testing. The DSA segment's margins have been squeezed by elevated NHP sourcing costs, and securing a more stable, cost-effective supply is a strategic priority.

These larger strategic moves are complemented by ongoing restructuring and efficiency initiatives aimed at trimming costs and improving margins across all segments. "We remain committed to driving our strategy forward, including through selective and strategic acquisitions that align with our core competencies; taking decisive actions to drive efficiency and process improvements that will deliver continued benefits; and by strengthening and refining our organization to enhance our speed and responsiveness," Mr. Foster stated.

The Path Forward in 2026

Looking ahead, Charles River's guidance for 2026 reflects both the lingering challenges and the anticipated benefits of its strategic actions. The company projects organic revenue to be anywhere from a 1.0% decline to flat for the year. This muted top-line forecast acknowledges that the market recovery may be gradual and that some segments, like the RMS business, face continued pressure.

However, the bottom-line forecast is notably more positive. The company expects non-GAAP EPS to grow by 4% to 9%, reaching a range of $10.70 to $11.20. This projected growth, even without a significant revenue increase, is expected to be driven by several factors: incremental cost savings from restructuring, the accretive earnings from the K.F. Cambodia acquisition, and a lower effective tax rate.

The guidance also assumes a story of two halves for the year. Based on the strong Q4 bookings, Charles River anticipates a return to organic revenue growth in the second half of 2026, for both the consolidated company and the critical DSA segment. This sets the stage for a pivotal year, as investors and the broader industry watch to see if the company's strategic overhaul and the nascent market recovery can successfully steer it back toward sustained growth.